postoperative complications following pancreaticoduodenectomy
Conditions
Interventions
experimental group:treatment with Ulinastatin
control:Placebo
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with malignant tumors located in Vater ampulla or in the inferior segment of common bile duct, head of pancreas,or duodenum; 2. Pancreaticoduodenectomy for patients with benign tumors, such as large inflammatory mass in the head of pancreas, or uncertain properties of mass in the head of pancreas during the operation; 3. The operation. combined with the pancreatoduodenectomy in order to achieve radical resection for patients with colon or gastric cancer invading the head of pancreas or duodenum; 4. Age from 18 to 80 years old; 5. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Cannot do the pancreatoduodenectomy during the Surgical exploration; 2. Patients cannot suffer the operation with the serious dieases, such as the heart, brain, lung, liver, or kidney dysfunction; 3. Patients with severe mental illness, including dementia; 4. known pregnant or lactating women; 5. Patients with a history of ulinastatin allergies, or highly allergic to ulinastatin; 6. Participated in the other drug experiments in the past three months; 7. Patients in a dying state.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence rate of complication; | — |
Countries
China
Contacts
Public ContactXubao Liu
Outcome results
None listed